Serca Pharmaceuticals presents first-in-class strategy for game-changing, post heart-attack cardioprotection at European Society of Cardiology Congress 2023
Evidence that 13-M, a unique small molecule disruptor of adrenergic SERCA2 activity reduces infarct size and preserves cardiac function Oslo, Norway – 29 August 2023 – Serca Pharmaceuticals, a Cardioprotection company that is developing 13-M, a novel first in class treatment for minimising tissue damage that occurs with blood reperfusion post myocardial infarction (MI) and […]